Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rb Health (Us) LLC is currently prosecuting 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's active applications are being reviewed by different technical teams within the Biotechnology & Pharmaceuticals sector. Such a structure requires the company to adapt to the specific requirements of 2 distinct art units.
The busiest examiner, SONG, JIANFENG, is currently handling 1 busiest examiner pending action. With a total of 2 pending office actions and 2 distinct examiners, the workload is split. The use of 2 distinct art units suggests that the company must address the specific requirements of different examination groups. This approach for 2 pending office actions means that 2 distinct examiners and 2 distinct art units are involved in the current prosecution landscape. This ensures that the company's progress is not limited to the findings of 1 examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18335355 | PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19027910 | PHARMACEUTICAL FORMULATION | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19027910 | PHARMACEUTICAL FORMULATION | SONG, JIANFENG | 1615 | §103§112DP | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18335355 | PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS | INAM, SAHAR | 1622 | §103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial